Sponsors
Ask me what this bill is really trying to do.
This is not an official government website.
Copyright © 2026 PLEJ LC. All rights reserved.
Treats a 'fentanyl-related substance' as an analogue of N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl] propanamide for purposes of the penalties in 21 U.S.C. 841(b)(1) and removes the requirement to prove the substance meets the controlled substance analogue definition in section 102.
Treats a 'fentanyl-related substance' as an analogue of N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl] propanamide for purposes of the penalties in 21 U.S.C. 960(b) and removes the requirement to prove the substance meets the controlled substance analogue definition in section 102.
Amends section 202(c) of the Controlled Substances Act (schedule I) by adding a new subsection (e) that defines and places a broad class of "fentanyl-related substances" into schedule I, including any material containing any quantity of such substances (and their salts, isomers, and salts of isomers) and listing five categories of structural modifications that qualify.
Adds fentanyl-related substances to Schedule I of the Controlled Substances Act and treats those chemically related compounds as fentanyl analogues for enforcement and penalty provisions. Any material containing any amount of a defined fentanyl-related substance — including salts, isomers, and salts of isomers — would be covered unless specifically exempted or placed in another schedule. Also changes criminal-applicability rules so prosecutors do not have to prove the separate statutory "analogue" definition for fentanyl-related substances under certain parts of the Controlled Substances Act and the Controlled Substances Import and Export Act. The law takes effect one day after enactment.
Adds a new subsection (e) to Section 202(c) of the Controlled Substances Act (Schedule I) so that fentanyl-related substances are included in Schedule I unless specifically exempted or listed in another schedule.
States that the inclusion covers any material, compound, mixture, or preparation that contains any quantity of fentanyl-related substances, and also covers their salts, isomers, and salts of isomers whenever those exist within the specific chemical designation.
Defines a fentanyl-related substance as any substance structurally related to fentanyl by replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not the monocycle is further substituted. (Modification A)
Includes substances that are fentanyl-related by substitution in or on the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halo, haloalkyl, amino, or nitro groups. (Modification B)
Includes substances that are fentanyl-related by substitution in or on the piperidine ring with alkyl, alkenyl, alkoxy, ester, ether, hydroxy, halo, haloalkyl, amino, or nitro groups. (Modification C)
Primary affected groups:
People who use illicit drugs and participants in illicit supply chains: Individuals who manufacture, distribute, import, export, or possess fentanyl‑related substances face Schedule I-level criminal exposure and associated penalties. The law broadens the set of compounds that trigger those penalties.
Law enforcement, prosecutors, and customs officials: Agencies gain a broader statutory basis to seize substances and prosecute fentanyl‑structure variants. Prosecutors will in many cases no longer have to prove the analogue test under section 102, lowering the evidentiary threshold in those prosecutions.
Research institutions, pharmaceutical developers, and clinical laboratories: Academic and commercial researchers working with fentanyl scaffolds or structurally related compounds may require Schedule I registrations, tighter security, and DEA authorizations, unless specific exemptions are issued. This will increase administrative burdens, slow some research pipelines, and raise compliance costs.
Healthcare providers, hospitals, and pharmacies: Entities that might encounter fentanyl variants in clinical settings or toxicology screens must reassess handling, disposal, and reporting obligations; certain inadvertent possession could raise regulatory consequences absent exemptions or clear guidance.
Courts and defense counsel: Legal proceedings will see fewer analogue‑definition disputes in the specified contexts, shifting litigation toward other elements (intent, trafficking quantity, mens rea). The change may generate constitutional challenges (e.g., vagueness, notice) that courts will need to resolve.
Overall effects:
Intended public-safety effect is to close enforcement gaps that arise when illicit chemists tweak fentanyl’s structure to evade specific listings. That can aid interdiction and criminal prosecution of illegal fentanyl analogues.
Secondary effects include increased regulatory compliance costs for legitimate researchers and potential chilling of some lawful scientific work if exemptions or clear administrative guidance are not promptly provided. There is also a risk of legal challenges testing the statute’s scope and constitutionality.
Agencies (DEA, DOJ, Customs/CBP, FDA) will need to update guidance, registration processes, and enforcement protocols quickly given the one‑day post‑enactment effective date.
Expand sections to see detailed analysis
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced February 6, 2025 by Scott Fitzgerald · Last progress February 6, 2025
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House